Astera Labs looks relatively expensive because similarly fast-growing AI infrastructure names trade at much lower multiples. Broadcom and Nvidia are at 14x, Credo at 15x and Lumentum at 18x; comparable peers look 50-80% cheaper. Astera is a great company and not necessarily expensive in absolute terms. Its roughly 2x multiple over Credo may persist, but the setup looks harder; with no valuation support, it could fall 50% if weakness continues. x.com  x.com  x.com  x.com 

The market is lagging badly on CXL demand for Astera Labs and Marvell. The next two quarters for both companies will show just how demanding the industry has already become. x.com 

Credo is a trade rather than a long-term hold because co-packaged optics is the technology that closes the copper-to-optics gap its retimers and active electrical cables fill. If CPO ramps faster than expected in the 2027 architecture cycle, those products get designed out. That is not a 2026 problem, but it is why a decelerating hyper-growth chipmaker can't keep a 15x sales multiple forever. Customer concentration, which hit the stock before, adds risk, and Credo fits no AI endgame theme. x.com  … Show more

Astera Labs is an incredible business, but its price leaves little margin of safety. Even an amazing decade, with revenue reaching $20B at 26% annual growth from about $1.9B, a 35% operating margin and a 30x multiple, makes it a roughly $158B company, about 3.6x from $44B, or around 13% a year before dilution. Slower revenue, lower margins, a lost customer, hyperscaler insourcing or tougher competition would erode that. Buying at half the price would make the risk/reward look amazing. x.com  … Show more

Credo's MicroVCSEL offers upside that does not appear priced in. Its copper and optics exposure, a SpaceX tailwind and fundamentals that look too good for its current valuation make it one of the tidiest AI infrastructure investments. x.com 

Astera Labs no longer looks expensive after falling 50% from its highs, trading below 35x NTM EBITDA with EBITDA expected to grow at a 60% CAGR for several years. Revenue is growing 105% YoY, with growth expected to accelerate for the next 2-3 quarters as margins expand. The stock is testing key support at its September 2025 highs, just above the 0.618 Fibonacci level and 200-day EMA. It is worth a look if the AI infrastructure buildout continues as planned. x.com 

Credo's leading AEC position and vertical integration keep its optics thesis bullish despite SpaceX moving away from 1.6T AECs. That shift is a genuine risk, but xAI has been in Credo's AEC ecosystem the longest, which could support ZeroFlap optics and its telemetry software. Credo's VCSEL-based ALCs were still ramping toward 2027, giving it another route as customers move to transceivers. x.com  x.com  x.com 

Astera Labs is an amazing business, but its valuation is getting quite pricey. x.com 

Astera Labs' key fundamentals are positive and growing nicely while the stock sits 35% off its highs, consolidating back toward its 200-day moving average. Ideal buying or accumulation is near or just above that average. x.com 

Astera Labs is an extremely good, unique business but still too expensive to buy. It is founder-led, growing fast and sits at the center of the AI infrastructure buildout, selling PCIe/CXL retimers and fabric switches to AWS, Azure and Google Cloud, but its valuation keeps it on the watchlist. x.com  x.com